EVOTEC SE ADR 1/2 O.N. (EVTA) - Net Assets
Based on the latest financial reports, EVOTEC SE ADR 1/2 O.N. (EVTA) has net assets worth €800.14 Million EUR (≈ $935.44 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.77 Billion ≈ $2.07 Billion USD) and total liabilities (€972.56 Million ≈ $1.14 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check EVTA asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €800.14 Million |
| % of Total Assets | 45.14% |
| Annual Growth Rate | -11.57% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 4.14 |
EVOTEC SE ADR 1/2 O.N. - Net Assets Trend (2021–2024)
This chart illustrates how EVOTEC SE ADR 1/2 O.N.'s net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of EVOTEC SE ADR 1/2 O.N. for the complete picture of this company's asset base.
Annual Net Assets for EVOTEC SE ADR 1/2 O.N. (2021–2024)
The table below shows the annual net assets of EVOTEC SE ADR 1/2 O.N. from 2021 to 2024. For live valuation and market cap data, see EVTA market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €952.52 Million ≈ $1.11 Billion |
-14.95% |
| 2023-12-31 | €1.12 Billion ≈ $1.31 Billion |
-5.67% |
| 2022-12-31 | €1.19 Billion ≈ $1.39 Billion |
-13.83% |
| 2021-12-31 | €1.38 Billion ≈ $1.61 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to EVOTEC SE ADR 1/2 O.N.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 45594900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €1.62 Billion | 170.59% |
| Total Equity | €952.52 Million | 100.00% |
EVOTEC SE ADR 1/2 O.N. Competitors by Market Cap
The table below lists competitors of EVOTEC SE ADR 1/2 O.N. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Xiamen East Asia Machinery Industrial Co. Ltd.
SHE:301028
|
$792.96 Million |
|
ZhuZhou QianJin Pharmaceutical Co Ltd
SHG:600479
|
$793.00 Million |
|
Wuhan Xingtu Xinke Electronics Co Ltd
SHG:688081
|
$793.10 Million |
|
Guangzhou Hongli Opto Electron
SHE:300219
|
$793.53 Million |
|
Hangzhou Heshun Technology Co.LTD.
SHE:301237
|
$792.06 Million |
|
National Grid PLC
LSE:NG
|
$791.76 Million |
|
Sejin Heavy Industries Co Ltd
KO:075580
|
$791.71 Million |
|
Hubei Century Network Technology Co Ltd
SHE:300494
|
$791.70 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in EVOTEC SE ADR 1/2 O.N.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,119,908,000 to 952,525,000, a change of -167,383,000 (-14.9%).
- Net loss of 196,078,000 reduced equity.
- Other factors increased equity by 28,695,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-196.08 Million | -20.59% |
| Other Changes | €28.70 Million | +3.01% |
| Total Change | €- | -14.95% |
Book Value vs Market Value Analysis
This analysis compares EVOTEC SE ADR 1/2 O.N.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.50x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.34x to 0.50x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €7.80 | €2.66 | x |
| 2022-12-31 | €6.71 | €2.66 | x |
| 2023-12-31 | €6.32 | €2.66 | x |
| 2024-12-31 | €5.36 | €2.66 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently EVOTEC SE ADR 1/2 O.N. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -20.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -24.60%
- • Asset Turnover: 0.42x
- • Equity Multiplier: 2.01x
- Recent ROE (-20.59%) is below the historical average (-6.81%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 15.64% | 34.87% | 0.28x | 1.62x | €77.74 Million |
| 2022 | -14.80% | -23.38% | 0.33x | 1.90x | €-294.37 Million |
| 2023 | -7.49% | -10.74% | 0.35x | 2.01x | €-195.90 Million |
| 2024 | -20.59% | -24.60% | 0.42x | 2.01x | €-291.33 Million |
Industry Comparison
This section compares EVOTEC SE ADR 1/2 O.N.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $778,651,241
- Average return on equity (ROE) among peers: -82.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| EVOTEC SE ADR 1/2 O.N. (EVTA) | €800.14 Million | 15.64% | 1.22x | $792.54 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $6.51 Billion | 11.81% | 0.39x | $635.99 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $534.88K | -741.80% | 26.77x | $113.81K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-1.01 Million | 0.00% | 0.00x | $134.78K |
| EQL PHARMA AB (7JK) | $154.75 Million | 19.98% | 0.85x | $148.83 Million |
| Alkermes plc (8AK) | $1.07 Billion | 1.94% | 0.48x | $5.00 Billion |
| OPTIMI HEALTH CORP. (8BN) | $9.58 Million | -63.03% | 0.52x | $17.99 Million |
| LABIANA HEALTH S.A.EO-10 (8RK) | $2.57 Million | 9.87% | 19.25x | $40.60 Million |
| CANNABIS POLAND AB ZY-10 (8TE) | $3.54 Million | -57.78% | 0.18x | $1.75 Million |
| Apontis Pharma AG (APPH) | $40.71 Million | -1.83% | 0.33x | $91.63 Million |
| CRAFTPORT CANNABIS CORP. (BBW0) | $-3.18 Million | 0.00% | 0.00x | $1.45 Million |
About EVOTEC SE ADR 1/2 O.N.
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more